<p>Disclosed is a compound represented by the formula (I) or (II) below, or a salt thereof. [In the formulae, ring A represents an optionally substituted ring (which is not a pyrrolidine, piperidine or piperazine); ring B represents an optionally substituted aromatic ring; ring D represents an optionally substituted ring; R<SUP>1</SUP> and R<SUP>2</SUP> independently represent a hydrogen atom or a substituent; R<SUP>3</SUP> represents a hydrogen atom or a C<SUB>1-6</SUB> alkyl group, or alternatively it combines with the ring A to form a non-aromatic ring; ring Aa represents an optionally substituted aromatic hydrocarbon; Y represents CH or N; Ra<SUP>1</SUP> represents an optionally substituted hydrocarbon group; and Ra<SUP>2</SUP> and Ra<SUP>3</SUP> independently represent a hydrogen atom or a substituent.] The compound has a DGAT inhibitory effect and is useful for treatment or improvement of diseases or conditions caused by high expression or high activation of DGAT.</p>
申请公布号
WO2006082952(A1)
申请公布日期
2006.08.10
申请号
WO2006JP301942
申请日期
2006.01.31
申请人
TAKEDA PHARMACEUTICAL COMPANY LIMITED;OGINO, MASAKI;NAKADA, YOSHIHISA;SHIMADA, MITSUYUKI;ASANO, KOUHEI;TAMURA, NORIKAZU;MASAGO, MINORI